3.24
+0.1068(+3.41%)
Currency In USD
Sector
Healthcare
Industry
Biotechnology
Employees
106
First IPO Date
June 30, 2003
| Name | Title | Pay | Year Born |
| Yaacov Yanay | President, Chief Executive Officer & Director | 558,417 | 1971 |
| Liat Zalts | CFO & Treasurer | 208,359 | 1984 |
| Arthur Machlenkin | Chief Scientific Officer | 0 | N/A |
| Lior Raviv | Chief Technology Officer | 0 | N/A |
| Nimrod Bar Zvi | Chief Commercial Officer | 0 | N/A |
| Ori Shalem | Vice President of Operations & Manufacturing | 0 | N/A |
| Efrat Kaduri | Chief Business Development Officer of Pharma | 0 | N/A |
| Hagit Gal | General Counsel | 0 | 1973 |
| Nofar Glaich-Dabach | Vice President of Human Resources | 0 | N/A |
| Orly Amiran | Chief Quality Officer | 0 | N/A |
Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.